JP2012500260A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500260A5
JP2012500260A5 JP2011523805A JP2011523805A JP2012500260A5 JP 2012500260 A5 JP2012500260 A5 JP 2012500260A5 JP 2011523805 A JP2011523805 A JP 2011523805A JP 2011523805 A JP2011523805 A JP 2011523805A JP 2012500260 A5 JP2012500260 A5 JP 2012500260A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
alkyl
independently
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/004704 external-priority patent/WO2010021693A2/en
Publication of JP2012500260A publication Critical patent/JP2012500260A/ja
Publication of JP2012500260A5 publication Critical patent/JP2012500260A5/ja
Pending legal-status Critical Current

Links

JP2011523805A 2008-08-18 2009-08-18 Mifモジュレーター Pending JP2012500260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18932708P 2008-08-18 2008-08-18
US61/189,327 2008-08-18
PCT/US2009/004704 WO2010021693A2 (en) 2008-08-18 2009-08-18 Mif modulators

Publications (2)

Publication Number Publication Date
JP2012500260A JP2012500260A (ja) 2012-01-05
JP2012500260A5 true JP2012500260A5 (OSRAM) 2012-10-04

Family

ID=41707595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523805A Pending JP2012500260A (ja) 2008-08-18 2009-08-18 Mifモジュレーター

Country Status (14)

Country Link
US (1) US20120040974A1 (OSRAM)
EP (1) EP2326631A4 (OSRAM)
JP (1) JP2012500260A (OSRAM)
KR (1) KR20110042374A (OSRAM)
CN (1) CN102186833A (OSRAM)
AU (1) AU2009283195A1 (OSRAM)
BR (1) BRPI0917394A2 (OSRAM)
CA (1) CA2733554A1 (OSRAM)
CL (1) CL2011000352A1 (OSRAM)
EA (1) EA201170349A1 (OSRAM)
IL (1) IL211170A0 (OSRAM)
MX (1) MX2011001872A (OSRAM)
PE (1) PE20110368A1 (OSRAM)
WO (1) WO2010021693A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044622A1 (en) * 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN102171210B (zh) 2008-08-05 2014-04-23 第一三共株式会社 咪唑并吡啶-2-酮衍生物
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
TW201107315A (en) 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
US20110257233A1 (en) * 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
CN103172578B (zh) * 2011-12-20 2016-09-14 天津市国际生物医药联合研究院 4-环末端取代2-1,2,3-三氮唑苯胺类化合物的制备和用途
CN103172579B (zh) * 2011-12-20 2017-02-22 天津市国际生物医药联合研究院 三氮唑苯胺类化合物的制备和用途
CN104428293B (zh) 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2970158B1 (en) * 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
WO2014200872A1 (en) 2013-06-09 2014-12-18 Rjs Biologics Llc Pharmaceutical compounds targeted by mif affinity-tethered moieties
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9382245B2 (en) 2013-10-11 2016-07-05 Yale University Compounds and methods for treating HIV infections
WO2015095052A1 (en) 2013-12-17 2015-06-25 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (mif) inhibitors
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
PT2929882T (pt) * 2014-04-10 2018-10-04 Mifcare Inibidores de mif
EP2944310B1 (en) 2014-05-16 2018-03-21 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
HUE042628T2 (hu) * 2014-10-01 2019-07-29 Janssen Pharmaceuticals Inc Mono- vagy diszubsztituált indolok mint dengue vírus replikáció inhibitorok
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10335399B2 (en) 2016-09-27 2019-07-02 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
ES2951809T3 (es) 2017-05-17 2023-10-25 Arcus Biosciences Inc Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
CN107188864B (zh) * 2017-07-28 2019-06-04 安徽师范大学 一种n-苄基苯并噁唑酮类化合物及其合成方法
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
CA3161323A1 (en) 2019-12-10 2021-06-17 Shanghai Zhimeng Biopharma, Inc. Compound having neuroprotective effect, preparation method therefor and use thereof
EP4237002A4 (en) * 2020-10-28 2025-02-12 University Health Network METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF
KR20230152692A (ko) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CN114028399A (zh) * 2021-12-18 2022-02-11 郑琳 一种mif抑制剂4-ipp在制备治疗脑胶质瘤药物的应用
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途
CN118490617B (zh) * 2024-05-14 2024-12-13 中山大学孙逸仙纪念医院 一种治疗皮肤型红斑狼疮的经皮微针贴片及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517587A1 (ru) * 1971-08-23 1976-06-15 Медицинска Академие (Инопредприятие) Способ получени производных 2оксфенилмочевины
FR2244506B1 (OSRAM) * 1973-06-26 1977-02-25 Inst Nat Sante Rech Med
DD111637A1 (OSRAM) * 1974-05-13 1975-03-05
DE2550959C3 (de) * 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0200345A3 (en) * 1985-03-30 1988-03-02 Beecham Group Plc Anti-allergic or anti-inflammatory substituted (hetero)-aralkylamino-ortho-phenols
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CA2249601A1 (en) * 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
ZA974030B (en) * 1996-05-15 1998-02-19 Bayer Ag Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
JP3783810B2 (ja) * 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
ES2249444T3 (es) * 2000-06-05 2006-04-01 Austria Wirtschaftsservice Gesellschaft Mit Beschrankter Haftung Hidrazonas heterociclicas como principios activos contra el cancer.
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
KR100837193B1 (ko) * 2000-08-14 2008-06-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 치환된 피라졸
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
YU52403A (sh) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
US6515176B1 (en) * 2001-12-03 2003-02-04 Eastman Kodak Company 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
EP2319838A1 (en) * 2002-06-07 2011-05-11 Cortical Pty Ltd Therapeutic Molecules and Methods-1
TWI347946B (en) * 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
FR2845998A1 (fr) * 2002-10-18 2004-04-23 Servier Lab Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
CA2584979A1 (en) * 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives
GB0423405D0 (en) 2004-10-21 2004-11-24 Novartis Ag Organic compounds
KR20070113252A (ko) * 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 mTOR억제제로서의 용도
US7576099B2 (en) * 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
KR20080019213A (ko) * 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
EP1893583B1 (en) * 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
KR20080090435A (ko) * 2005-12-21 2008-10-08 코티컬 피티와이 리미티드 Mif 저해제
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2460800A1 (en) * 2006-03-08 2012-06-06 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
JP5190062B2 (ja) * 2006-10-12 2013-04-24 ノバルティス アーゲー Iap阻害剤としてのピロリジン誘導体
DE102007026341A1 (de) * 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
TWI428091B (zh) * 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
CN101970432B (zh) * 2008-01-25 2014-05-28 杜邦公司 杀真菌杂环化合物
WO2009108720A2 (en) * 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors

Similar Documents

Publication Publication Date Title
JP2012500260A5 (OSRAM)
JP2010540525A5 (OSRAM)
JP2014508811A5 (OSRAM)
JP2011507896A5 (OSRAM)
JP2011500638A5 (OSRAM)
JP2013542218A5 (OSRAM)
JP2010280684A5 (OSRAM)
UA104997C2 (uk) Аміди азотвмісних насичених гетероциклів та 3,5-діаміно-6-хлор-2-піразинкарбонової кислоти як лікарський засіб
JP2010536887A5 (OSRAM)
JP2015537020A5 (OSRAM)
JP2011500621A5 (OSRAM)
JP2013510120A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2014506907A5 (OSRAM)
ME02754B (me) Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
JP2014507455A5 (OSRAM)
JP2016527220A5 (OSRAM)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2015501833A5 (OSRAM)
JP2015516420A5 (OSRAM)
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2016501250A5 (OSRAM)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2018529737A5 (OSRAM)
JP2015514063A5 (OSRAM)